2-MeOPP positive hair result in case of urapidil treatment

Alexandr Gish; Dulciane Baes; Camille Richeval; Jean-François Wiart; Florian Hakim; Corentin Grenier; Delphine Allorge; Jean-Michel Gaulier

doi:10.1002/dta.3380

2-MeOPP positive hair result in case of urapidil treatment

Drug Test Anal. 2023 Sep;15(9):994-997. doi: 10.1002/dta.3380. Epub 2022 Oct 13.

Authors

Alexandr Gish¹, Dulciane Baes², Camille Richeval^{1

3}, Jean-François Wiart¹, Florian Hakim^{1

3}, Corentin Grenier¹, Delphine Allorge^{1

3}, Jean-Michel Gaulier^{1

3}

Affiliations

¹ CHU Lille, Unité Fonctionnelle de Toxicologie, Lille, France.
² CHU Lille, Service de Néphrologie, Lille, France.
³ URL 4483 - IMPECS - IMPact de l'Environnement Chimique sur la Santé humaine, Université de Lille, Lille, France.

PMID: 36229419
DOI: 10.1002/dta.3380

Abstract

The metabolism of urapidil to 2-MeOPP induces the risk of detection of 2-MeOPP in biological samples (blood, urine and hair) in case of urapidil treatment. This is supported by two case reports and an in vitro study of urapidil metabolism.

Publication types

Case Reports
Letter

MeSH terms

Antihypertensive Agents
Humans
Hypertension* / drug therapy
Piperazines

Substances

Antihypertensive Agents
urapidil
Piperazines